Summary & Overview
HCPCS G8506: Patient Receiving ACE Inhibitor or ARB Therapy
HCPCS Level II code G8506 documents that a patient is receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy. Nationally, this code serves as a clinical quality and care-continuity marker for management of hypertension, heart failure, diabetic nephropathy, and other cardiovascular or renal conditions where RAAS blockade is indicated. Accurate use of G8506 supports quality reporting, care coordination, and medication reconciliation efforts across outpatient settings.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how G8506 is applied across typical outpatient sites of service and summarizes benchmarks and common billing practices tied to this therapy indicator.
Readers will find: an explanation of the code’s clinical context; typical sites of service and service type; payer coverage considerations and commonly used modifiers; and where available, benchmark framing and policy implications relevant to national reporting programs. The summary clarifies which inputs were available and notes where data elements were not provided.
Billing Code Overview
HCPCS Level II code G8506 indicates a patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy. The service reflects documentation that a patient is on ACE inhibitor or ARB medication as part of their clinical management.
-
Service type: Medication therapy documentation and medication management indicator
-
Typical site of service: Ambulatory outpatient settings, primary care offices, cardiology clinics, and other outpatient clinics where chronic cardiovascular or renal disease is managed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hypertension and/or heart failure under chronic outpatient management who is prescribed an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB). The clinical workflow begins in primary care, cardiology, or nephrology where the clinician documents initiation, continuation, dose adjustment, or monitoring of ACE inhibitor/ARB therapy during an office visit or chronic care management encounter. Encounters commonly include medication reconciliation, review of blood pressure readings, assessment of renal function and serum potassium, counseling on adverse effects (cough, angioedema, hyperkalemia), and coordination with pharmacy for dispensation. Typical site of service is an outpatient clinic, ambulatory care center, or telehealth visit; this code documents that the patient is receiving ACE inhibitor or ARB therapy as part of their management plan. The patient scenario may involve titration of lisinopril, enalapril, losartan, or valsartan for blood pressure control or for guideline-directed therapy in systolic heart failure, with scheduled laboratory monitoring and follow-up visits to assess efficacy and safety.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Services | Use when work or resources exceed usual for the visit due to complexity of managing ACE inhibitor/ARB therapy (e.g., extensive medication management, multiple comorbidities). |